TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05999201

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: craniocervical neural mobilization
Description: the patients will receive The craniocervical neural mobilization in the form of passive craniocervical flexion in which An anterior rotation of the head will be done which stimulates the meninges.To increase mechanical stress in the nervous system, patients will be asked to do a descent and retropulsion of the shoulders while gradually extending both elbows. in addition to Passive lateral cervical sliding and Craniocervical flexion with mouth opening.The neural mobilization should be mild, progressive, and slow. The protocol lasted 15 minutes and also the patients will receive selected physiotherapy program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physiotherapy program
Description: the patients will receive selected physiotherapy program in the form of Suboccibital muscles inhibition suboccipital inhibition technique (SIT), from supine lying position, the therapist will sit at the patient's head head with the elbows rested on the surface of the table. Then, the therapist will place both hands behind the head of the patient with the palms facing upwards, the fingers flexed, and the finger pads positioned on the posterior arch of the atlas to allow the occiput to rest in the palm of the hands. the patients will receive also trigger point release technique in the form of An ischemic compression for sternocleidomastoid muscle, temporal muscle, upper trapezius muscle and splines muscles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physiotherapy program
Description: the patients will receive selected physiotherapy program in the form of Suboccibital muscles inhibition suboccipital inhibition technique (SIT), from supine lying position, the therapist will sit at the patient's head head with the elbows rested on the surface of the table. Then, the therapist will place both hands behind the head of the patient with the palms facing upwards, the fingers flexed, and the finger pads positioned on the posterior arch of the atlas to allow the occiput to rest in the palm of the hands. the patients will receive also trigger point release technique in the form of An ischemic compression for sternocleidomastoid muscle, temporal muscle, upper trapezius muscle and splines muscles
Study: NCT05490368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bed mattress sensor system
Description: The new sensor pad can detect any bed-exit activities, including stirring, sitting up, leaving, and out-of-bed. Audible message and alert to care staff can be customised in each participant. Whenever the system detects a change of bed-exit activity, an audible message will be played in the control box next to the resident's bed reminding the resident not to leave and that a care staff shall arrive shortly. Care staff at the nurse station will simultaneously receive the alert, as a sound and a visual figure on the dashboard, with the location and body position of the resident, and be prompted for a rapid and appropriate response. Care staff are allowed to customise each resident's alert settings, including time to alert and notification method.
Study: NCT05611476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Muscular Therapy for low back pain
Description: Psychologically informed physiotherapy which used biofeedback training to reduce muscle overactivity and improve postural control
Study: NCT06328205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rehabilitation therapy
Description: Rehabilitation therapy includes Diet management: Avoiding consumption of irritant foods and beverages, such as spicy foods, caffeine, alcohol, and acidic foods. Controlling portion sizes and meal timing, and adopting smaller, more frequent meals.~Lifestyle adjustments: Avoiding lying down or bending immediately after meals, maintaining a sitting or upright position for at least 2 hours. Adjusting sleeping positions by elevating the head of the bed to reduce nighttime acid reflux. Avoiding excessive exertion and managing stress levels.~Rehabilitation training: Strengthening the control of esophageal and gastric muscles through rehabilitation exercises to improve the function of the gastroesophageal sphincter and prevent gastric fluid reflux.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glossopharyngeal Nerve Block
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
Study: NCT05758064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duphaston
Description: 10 mg tablet will be given twice

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prolutex
Description: subcutaneous injection daily
Study: NCT06284876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilaprazole
Description: Ilaprazole 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ilaprazole Placebo
Description: Placebo of Ilaprazole 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole Placebo
Description: Placebo of Lansoprazole 15 mg
Study: NCT06291272

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: 15 g psyllium + 15 g inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcellulose
Description: 15 g methylcellulose + 15 g inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inulin
Description: 15 inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 15 inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 15 maltodextrin
Study: NCT06328205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\]. once a day. 1 ml per time.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. 1 milliliter of normal saline will be used for injection.
Study: NCT05131841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipterbin Combined With Vinorelbine
Description: 1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipterbin Combined With Vinorelbine
Description: 1. Cipterbin combined with Vinorelbine Injection every week in the treatment of patients with HER2-positive metastatic breast cancer~2. Cipterbin combined with Vinorelbine Injection every three weeks in the treatment of patients with HER2-positive metastatic breast cancer
Study: NCT05654376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: Participant's creativity is stimulated by visual arts materials and various art therapy techniques, in relation to 6 topics: self-care, stress management, flourishing caregiving, challenging caregiving, loss and grief, and sense of professional meaning.~The strategy consists of stimulating an observant and symbolic gaze, facilitating visual expression, promoting communication about what it has been expressed, and gather learning from the multidimensional impact of the creative art process (sensations, emotions, cognitions and spiritual experiences).
Study: NCT05629780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resuscitation fluid
Description: Cristalloid fluids given as a resuscitational intervention
Study: NCT05186805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapinarof cream, 1%
Description: Tapinarof cream, 1% applied topically once daily
Study: NCT05482113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Liposomal Bupivacaine (Exparel) Brachial Plexus Block for Arthroscopic Rotator Cuff Repair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hcl 0.25% Inj
Description: Standard 0.25% Bupivacaine Brachial Plexus Block for Arthroscopic Rotator Cuff Repair
Study: NCT06270381

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMPOWER
Description: The EMPOWER intervention (Enhancing and Mobilizing the POtential for Wellness and Emotional Resilience) is a cognitive-behavioral and acceptance-based intervention divided into six modules.In the current application, this intervention is conducted in 6 in-presence or online 50-minute sessions and 2 booster sessions 2 and 4 weeks after the final intervention. It is a manualized treatment in which each session has a specific goal: 1st) Welcome, initial assessment and adherence to the intervention; 2nd) Psychoeducation and transmission of resources for stabilization; 3rd) Psychoeducation on Trauma, Grief and Cognitive-Behavioral Model; 4th)Promoting Experiential Acceptance; 5th) Imagined dialogue; 6th) Coping Training; and two final boosting sessions. In every session, the impact of the previous consultation and evolution is evaluated. This intervention was developed by Lichtenthal et al., 2022.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: The treatment as usual (TAU) consists of supportive psychotherapy based on a non-structured and integrative method that focuses on the development of more adaptive coping strategies, understanding and working on the patient's internal models of self, others, and the world. The TAU will be considered during the same period as the EMPOWER intervention.
Study: NCT06416774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.05mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.1mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for radioactive counts for pharmacokinetic analysis and safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-HX01 Injection(0.07mCi/kg)
Description: The study is divided into three stages, including screening period, administration period and follow-up observation period. The maximum screening period is 7 days. Eligible subjects will receive intravenous injection of the experimental drug 68Ga-HX01 on Day 1 of the study and undergo PET imaging, while blood and urine are collected for safety monitoring.~They will return to the study center for safety checks on Day 2 after injection and phone follow-up on Day 7 for adverse events and drug combinations/treatments.
Study: NCT05403541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo SC
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo SC
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC bi-weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT04850300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee prosthesis with medial condylar stabilization
Description: Surgery will be done of Total knee prosthesis with medial condylar stabilization

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee prosthesis with central pivot stabilization
Description: Surgery will be done of Total knee prosthesis with central pivot stabilization
Study: NCT05668754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Serdexmethylphenidate
Description: Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate
Description: Participants randomized to active drug will receive their optimized dose according to a dosing regimen set by randomization at the start of the OLTP. The 4 possible oral SDX doses are 80, 160, 240, or 320 mg/day. The optimal SDX dose will be determined during the 5-week OLTP preceding the 2-week DBWP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants randomized to placebo will receive matching placebo capsules to the optimized dose established at the end of the OLTP, according to a dosing regimen set by randomization at the start of the OLTP.
Study: NCT06219239

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: KL003 cell injection Drug Product
Description: No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene
Study: NCT06075758

Intervention type: OTHER
Intervention: ribociclib
Description: There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription.

Intervention type: OTHER
Intervention: ribociclib
Description: There is no treatment allocation for NIS trials, patients on administered ribociclib by prescription will be enrolled.~Treatment plan represents the prescription.
Study: NCT05046795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revefenacin 175 mcg in 3 ML Inhalation Solution
Description: Revefenacin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo inhalation solution QD
Description: Placebo
Study: NCT03782155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glutamine supplementation
Description: powder 14g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMB
Description: powder 3g

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: powder 17g
Study: NCT06188065

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood eosinophil count
Description: To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood eosinophil count
Description: To determine the time it takes for blood eosinophil count to recover to baseline stable state following severe exacerbation of COPD associated with admission eosinopenia and to explore independent factors associated with admission eosinopenia.
Study: NCT04290026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide versus granisetron
Description: ِِِِAssessment of the effect of metoclopramide versus granisetron on gastric volume in patients undergoing caesarean section by us
Study: NCT06495736

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Experimental: ROSE technique stain
Description: The ROSE technical group uses Diff-Quick stain for diagnosis
Study: NCT05913622

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump
Description: An IABP is placed percutaneously into the thoracic aorta and supports the heart through synchronized inflation and deflation of a balloon.
Study: NCT05583591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined cataract surgery with Hydrus microstent
Description: Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined cataract surgery with Hydrus microstent
Description: Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined cataract surgery with iStent Inject W
Description: Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined cataract surgery with iStent Inject W
Description: Device designed to help lower intraocular pressure by improving aqueous outflow through the trabecular meshwork. Used in combination with cataract surgery.
Study: NCT06003387

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CSL222 (AAV5-hFIXco-Padua)
Description: Administered as a single IV infusion.
Study: NCT06565507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole single dose
Description: Subjects will receive active oxfendazole, 20 mg/kg/day, orally, as a single dose. Oxfendazole placebo will be used at days 4 and 7 to maintain blinding between the two intervention arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxfendazole three doses
Description: Subjects will receive active oxfendazole, 20 mg/kg/day, orally, in three days (1, 4 and 7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole plus praziquantel regime
Description: Subjects will receive a combination of albendazole plus praziquantel, as a standard treatment for brain cysticercosis (neurocysticercosis), orally, for ten days. Albendazole will be given at 15/kg/d and praziquantel at 50/kg/d.
Study: NCT06568601

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic and polygenic risk testing
Description: The intervention involves: genetic testing; interpretation; and prior to and shortly following an upcoming appointment, communication to patients and providers about the patients' predicted statin efficacy and toxicity, genetic risk for CVD, and individualized recommended statin type/dose.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: The control condition involves receipt of a report highlighting the risk of cardiovascular disease and benefits of statins (without genetic test
Study: NCT04652960

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Punch Biopsy
Description: Undergo punch biopsies
Study: NCT05111613

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter-Directed Thrombolysis
Description: Catheter-Directed Thrombolysis for pulmonary embolism (any commercially available CDT system)

Intervention type: DEVICE
Group type: OTHER
Intervention: FlowTriever System
Description: Mechanical thrombectomy for pulmonary embolism

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FlowTriever System
Description: Mechanical thrombectomy for pulmonary embolism
Study: NCT05480202

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic block technique
Description: Manual compression of the healthy lung during expiration associated with the use of invasive or non invasive mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Designed chest physical therapy program
Description: Percussion, vibration and postural drainage